Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Prostate Cancer
Darolutamide Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer
By
Anne Rowe
ASCO GU 2023 Highlights
,
Prostate Cancer
March 2023, Vol 13, No 3
An analysis from the ARASENS trial showed that the addition of darolutamide (Nubeqa) to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high-volume and high-risk disease and should be considered the new standard of care for this patient population.
Read More ›
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations
By
Patricia Stewart
Prostate Cancer
July 2022, Vol 12, No 7
The addition of the PARP inhibitor niraparib (Zejula) to abiraterone acetate (Zytiga) plus prednisone (AAP) led to a significant improvement in radiographic progression-free survival (PFS) versus AAP alone in men with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations, according to the final analysis of the primary end point of a phase 3 trial.
Read More ›
Abiraterone Added to ADT Improves Survival in Patients with High-Risk Prostate Cancer
By
Patricia Stewart
Prostate Cancer
January 2022, Vol 12, No 1
Two years of abiraterone acetate (Zytiga) plus prednisone added to androgen-deprivation therapy (ADT) improved metastasis-free survival and overall survival compared with ADT alone in men with nonmetastatic castration-sensitive prostate cancer, whereas the addition of enzalutamide (Xtandi) to ADT had no benefit, and much greater toxicity.
Read More ›
Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer
Interview with the Innovators
,
Prostate Cancer
Interview with the Innovators – December 2021
A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC.
Read More ›
Clinical NCCN Risk Classification Suboptimal for Some African-American Men with Prostate Cancer
By
Charlie Dawson
Prostate Cancer
November 2021, Vol 11, No 11
Preliminary results from the first prospective study of a genomic classifier for African-American men suggest that both disparities in access to care and biological factors may be responsible for the increased incidence and mortality in this patient population. The study also identified a significant age difference between African-American and non–African-American men with respect to high genomic risk. These findings were presented during the American Society of Clinical Oncology 2021 virtual annual meeting.
Read More ›
¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
By
Patricia Stewart
ASCO GU Cancers Highlights
,
Prostate Cancer
April 2021, Vol 11, No 4
Cabazitaxel (Jevtana) is approved as third-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC) after treatment with docetaxel and an androgen receptor inhibitor. A new phase 2 clinical trial shows that the radionuclide therapy that targets the prostate-specific membrane antigen (PSMA),
177
Lu-PSMA-617, reduced the risk for disease progression or death by 37% compared with cabazitaxel in men with previously treated metastatic CRPC. Moreover, the TheraP study showed that patients who received
177
Lu-PSMA-617 had fewer side effects and improved quality of life compared with patients who received cabazitaxel.
Read More ›
Rucaparib Demonstrates Antitumor Activity in Men with BRCA-mutated mCRPC
In the Literature
,
Prostate Cancer
Web Exclusives
Rucaparib (Rubraca, Clovis Oncology) demonstrated promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious
BRCA
alteration, according to results of a study published online in the
Journal of Clinical Oncology
.
Read More ›
Study Shows Active Surveillance Not Associated with Higher Mortality in Black Men with Prostate Cancer
In the Literature
,
Prostate Cancer
Web Exclusives
Black men with low-risk prostate cancer who were on active surveillance had an increased risk for disease progression and definitive treatment compared with their non-Hispanic White counterparts, but not increased mortality, according to the results of a recent study.
Read More ›
Relugolix May Become New Standard of Care for Advanced Prostate Cancer
By
Patricia Stewart
Prostate Cancer
August 2020, Vol 10, No 8
Oral relugolix given daily is superior to standard androgen-deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting (Shore ND, et al.
N Engl J Med
. 2020;382:2187-2196).
Read More ›
Early Phase 2 Data Promising for 177Lutetium PSMA-617 in Metastatic Prostate Cancer
By
Patricia Stewart
Prostate Cancer
August 2020, Vol 10, No 8
arly results from the phase 2 TheraP clinical trial show that the targeted radiation therapy
177
Lutetium PSMA-617 (Lu-PSMA) significantly improved prostate-specific antigen (PSA) response compared with standard cabazitaxel in men with metastatic castration-resistant prostate cancer (CRPC) that progressed after docetaxel therapy.
Read More ›
Page 1 of 4
1
2
3
4
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes